Physician profile
Madison C Thomas
NPI 1164072393
$123.82
in general payments reported to CMS, 2019-2025
4 companies · $43.10 in 2025
The $43.10 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.40 · 2023: $36.82 · 2024: $29.50 · 2025: $43.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.22 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $29.50 | 2024 | Ryaltris |
| Ucb, INC. | $23.68 | 2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $19.42 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.